Cargando…

Low CD8(+) T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44(+)/CD133(+) Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer

Cancer immunotherapy targeting immune checkpoints has exhibited promising clinical outcomes in many cancers, but it offers only limited benefits for pancreatic cancer (PC). Cancer stem cells (CSCs), a minor subpopulation of cancer cells, play important roles in tumor initiation, progression, and dru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Ya-Chin, Chao, Ying-Jui, Hsieh, Min-Hua, Tung, Hui-Ling, Wang, Hao-Chen, Shan, Yan-Shen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520688/ https://www.ncbi.nlm.nih.gov/pubmed/30991694 http://dx.doi.org/10.3390/cancers11040541

Ejemplares similares

Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma
por: Hou, Ya-Chin, et al.
Publicado: (2014)

The Potential Role of CD44 and CD133 in Colorectal Stem Cell Cancer
por: Abdou Hassan, Wael, et al.
Publicado: (2022)

Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer
por: WANG, CHUNXIA, et al.
Publicado: (2012)

Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis
por: Durko, L., et al.
Publicado: (2017)

Cancer Stem Cell Markers CD44, CD133 in Primary Gastric Adenocarcinoma
por: Nosrati, Anahita, et al.
Publicado: (2014)

Corrigendum to “Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis”
por: Durko, L., et al.
Publicado: (2017)

Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis
por: Han, Zhengquan, et al.
Publicado: (2015)

CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure
por: Tsunekuni, Kenta, et al.
Publicado: (2019)

Prognostic value of CD133(+) CD54(+) CD44(+) circulating tumor cells in colorectal cancer with liver metastasis
por: Fang, Chao, et al.
Publicado: (2017)

Cobalt ferrite nanoparticle for the elimination of CD133+CD44(+) and CD44(+)CD24(−), in breast and skin cancer stem cells, using non-ionizing treatments
por: Khalili Najafabad, Bahareh, et al.
Publicado: (2023)

Expression of the Cancer Stem Cell Markers CD44 and CD133 in Colorectal Cancer: An Immunohistochemical Staining Analysis
por: Hong, Injae, et al.
Publicado: (2015)

Role of CD44(high)/CD133(high) HCT-116 cells in the tumorigenesis of colon cancer
por: Zhou, Jin-Yong, et al.
Publicado: (2016)

Brca1 breast tumors contain distinct CD44(+)/CD24(- )and CD133(+ )cells with cancer stem cell characteristics
por: Wright, Mollie H, et al.
Publicado: (2008)

Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells
por: Sahlberg, Sara Häggblad, et al.
Publicado: (2014)

Immunohistochemical Detection of Cancer Stem Cell Related Markers CD44 and CD133 in Metastatic Colorectal Cancer Patients
por: Pitule, Pavel, et al.
Publicado: (2014)

Dual role of CD44 isoforms in ampullary adenocarcinoma: CD44s predicts poor prognosis in early cancer and CD44ν is an indicator for recurrence in advanced cancer
por: Wu, Cheng-Lin, et al.
Publicado: (2015)

Effects of flavopiridol on critical regulation pathways of CD133(high)/CD44(high) lung cancer stem cells
por: Bozok Cetintas, Vildan, et al.
Publicado: (2016)

Induced growth inhibition, cell cycle arrest and apoptosis in CD133(+)/CD44(+) prostate cancer stem cells by flavopiridol
por: SONER, BURAK CEM, et al.
Publicado: (2014)

CD133(+)CD54(+)CD44(+) circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer
por: Fang, Chao, et al.
Publicado: (2016)

Identification and characterization of CD133(+)CD44(+) cancer stem cells from human laryngeal squamous cell carcinoma cell lines
por: Wang, Jue, et al.
Publicado: (2017)

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010)

Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer
por: Lugli, A, et al.
Publicado: (2010)

Tumour stem cell markers CD133 and CD44 are useful prognostic factors after surgical resection of pancreatic neuroendocrine tumours
por: Sun, Zhonghai, et al.
Publicado: (2020)

Prospectively Isolated Cancer-Associated CD10(+) Fibroblasts Have Stronger Interactions with CD133(+) Colon Cancer Cells than with CD133(−) Cancer Cells
por: Cui, Lin, et al.
Publicado: (2010)

Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8(+) T-Cell Infiltration in Pancreatic Cancer
por: Li, Zhenchong, et al.
Publicado: (2022)

Downregulation of CD44 reduces doxorubicin resistance of CD44(+)CD24(−) breast cancer cells
por: Van Phuc, Pham, et al.
Publicado: (2011)

Expression profiling of stem cell signaling alters with spheroid formation in CD133(high)/CD44(high) prostate cancer stem cells
por: OKTEM, GULPERI, et al.
Publicado: (2014)

Dual-targeting nanomicelles with CD133 and CD44 aptamers for enhanced delivery of gefitinib to two populations of lung cancer-initiating cells
por: Huang, Xiaolong, et al.
Publicado: (2020)

Single-cell sequencing reveals CD133(+)CD44(−)-originating evolution and novel stemness related variants in human colorectal cancer
por: Zhang, Xiaoyan, et al.
Publicado: (2022)

Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme
por: Brown, Daniel V., et al.
Publicado: (2015)

Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran
por: Nosrati, Anahita, et al.
Publicado: (2016)

CD44V3, an Alternatively Spliced Form of CD44, Promotes Pancreatic Cancer Progression
por: Zhu, Hanzhang, et al.
Publicado: (2022)

Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity
por: Brown, Daniel V., et al.
Publicado: (2017)

Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure
por: Fritzenwanger, M, et al.
Publicado: (2009)

A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers
por: Lee, Yi-Jen, et al.
Publicado: (2016)

THE CD133-POSITIVE COLON CANCER CELL PHENOTYPE IS MORE INTERACTIVE WITH THE TUMOR MICROENVIRONMENT COMPARED TO CD133-NEGATIVE CELL
por: Chao, Celia, et al.
Publicado: (2011)

Gliomasphere marker combinatorics: multidimensional flow cytometry detects CD44+/CD133+/ITGA6+/CD36+ signature
por: Erhart, Friedrich, et al.
Publicado: (2018)

Prostate Cancer Stem Cells: The Role of CD133
por: Yang, Jianhui, et al.
Publicado: (2022)

The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells
por: Tsubouchi, Kento, et al.
Publicado: (2017)

CD133 Expression and Identification of CD133/nestin Positive Cells in Rhabdomyosarcomas and Rhabdomyosarcoma Cell Lines
por: Sana, Jiri, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_56jfr2g0d95840a9pnat4usbuh